CA2885180C - Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives - Google Patents

Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives Download PDF

Info

Publication number
CA2885180C
CA2885180C CA2885180A CA2885180A CA2885180C CA 2885180 C CA2885180 C CA 2885180C CA 2885180 A CA2885180 A CA 2885180A CA 2885180 A CA2885180 A CA 2885180A CA 2885180 C CA2885180 C CA 2885180C
Authority
CA
Canada
Prior art keywords
phenyl
triazol
methanone
pyrrolidin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2885180A
Other languages
English (en)
French (fr)
Other versions
CA2885180A1 (en
Inventor
Martin Bolli
Christoph Boss
Christine Brotschi
Markus Gude
Bibia Heidmann
Thierry Sifferlen
Jodi T. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CA2885180A1 publication Critical patent/CA2885180A1/en
Application granted granted Critical
Publication of CA2885180C publication Critical patent/CA2885180C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
CA2885180A 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives Active CA2885180C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12188019 2012-10-10
EP12188019.9 2012-10-10
EP13157809 2013-03-05
EP13157809.8 2013-03-05
PCT/IB2013/059233 WO2014057435A1 (en) 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives

Publications (2)

Publication Number Publication Date
CA2885180A1 CA2885180A1 (en) 2014-04-17
CA2885180C true CA2885180C (en) 2021-03-02

Family

ID=49765598

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2885180A Active CA2885180C (en) 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives

Country Status (16)

Country Link
US (1) US9493446B2 (enExample)
EP (1) EP2906553B1 (enExample)
JP (1) JP6244365B2 (enExample)
KR (1) KR102151288B1 (enExample)
CN (1) CN104703980B (enExample)
AR (1) AR092955A1 (enExample)
AU (1) AU2013328301A1 (enExample)
BR (1) BR112015007516A2 (enExample)
CA (1) CA2885180C (enExample)
EA (1) EA201500399A1 (enExample)
IL (1) IL238052A0 (enExample)
MX (1) MX2015004638A (enExample)
PH (1) PH12015500627A1 (enExample)
SG (1) SG11201502493XA (enExample)
TW (1) TW201414727A (enExample)
WO (1) WO2014057435A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2855453T (lt) 2012-06-04 2017-02-27 Actelion Pharmaceuticals Ltd. Benzimidazolo prolino dariniai
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
PT3077389T (pt) 2013-12-03 2017-12-15 Idorsia Pharmaceuticals Ltd Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
US9938276B2 (en) 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2017012502A1 (en) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
WO2017088759A1 (en) 2015-11-23 2017-06-01 Sunshine Lake Pharma Co., Ltd. OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
CN106986859B (zh) * 2016-01-20 2020-02-11 广东东阳光药业有限公司 吲哚衍生物及其用途
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
KR20190108118A (ko) 2017-01-06 2019-09-23 유마니티 테라퓨틱스, 인크. 신경계 장애의 치료를 위한 방법
JP7012703B2 (ja) * 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
CN108794454B (zh) * 2017-04-27 2023-08-15 广东东阳光药业股份有限公司 一种咪唑环化合物的制备方法
EP3619199B1 (en) * 2017-05-03 2021-07-07 Idorsia Pharmaceuticals Ltd Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
WO2019018795A1 (en) * 2017-07-20 2019-01-24 Yumanity Therapeutics COMPOUNDS AND USES THEREOF
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
JP7025542B2 (ja) * 2017-10-26 2022-02-24 サウザーン リサーチ インスチチュート Ｔｇｆ－ベータ阻害剤としてのオキサジアゾール及びチアジアゾール
MX2020009942A (es) 2018-03-23 2021-01-08 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EP3784234A1 (en) 2018-04-25 2021-03-03 Yumanity Therapeutics, Inc. Compounds and uses thereof
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
EP3917616B1 (en) 2019-01-31 2025-06-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds and use thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
JP7681113B2 (ja) * 2021-02-02 2025-05-21 メッドシャイン ディスカバリー インコーポレイテッド テトラヒドロピロロ環化合物及びその使用
TW202400149A (zh) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物
US11919872B1 (en) 2023-10-11 2024-03-05 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
US11897850B1 (en) 2023-10-11 2024-02-13 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound
US11912675B1 (en) 2023-10-11 2024-02-27 King Faisal University N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound
US11891366B1 (en) 2023-10-12 2024-02-06 King Faisal University 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
CN119613393A (zh) * 2024-11-13 2025-03-14 深圳华津生物科技有限公司 Trpc5抑制剂及其制备方法和应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
AUPQ253199A0 (en) 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
PT1289955E (pt) 2000-06-16 2005-08-31 Smithkline Beecham Plc Piperidinas para utilizacao como antagonistas dos receptores da orexina
WO2002044172A1 (en) 2000-11-28 2002-06-06 Smithkline Beecham P.L.C. Morpholine derivatives as antagonists of orexin receptors
JP2004534026A (ja) 2001-05-05 2004-11-11 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体
JP4309135B2 (ja) 2001-05-05 2009-08-05 スミスクライン ビーチャム ピー エル シー Ｎ−アロイルサイクリックアミン
PL367677A1 (en) 2001-06-28 2005-03-07 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
DE10240818A1 (de) 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
WO2004026866A1 (en) 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
PE20050226A1 (es) 2003-06-04 2005-05-18 Aventis Pharma Sa Productos aril-heteroaromaticos y composiciones que los contienen
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
HRP20150371T1 (hr) 2004-03-01 2015-05-08 Actelion Pharmaceuticals Ltd. Supstituirani derivati 1,2,3,4-tetrahidroizokinolina
WO2005113522A1 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Azole carboxamide inhibitors of bacterial type iii protein secretion systems
EP1604989A1 (en) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
US7269781B2 (en) 2004-06-25 2007-09-11 Hewlett-Packard Development Company, L.P. Discrete universal denoising with reliability information
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
HUP0500920A2 (en) 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
AU2007226203A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
US8618102B2 (en) 2006-07-14 2013-12-31 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
AU2007275301A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
BRPI0713187A2 (pt) * 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
PL2069332T3 (pl) 2006-08-15 2011-07-29 Actelion Pharmaceuticals Ltd Związki azetydynowe jako antagoniści receptorów oreksynowych
EP2079690B1 (en) 2006-09-29 2010-09-15 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.1.0]hexane derivatives
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
WO2008065626A2 (en) 2006-12-01 2008-06-05 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
US20100222328A1 (en) 2007-05-14 2010-09-02 Hamed Aissaoui 2-cyclopropyl-thiazole derivatives
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9150556B2 (en) 2007-05-22 2015-10-06 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
BRPI0811978A2 (pt) 2007-06-01 2014-11-18 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e uso dos compostos
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
CA2691373A1 (en) 2007-07-03 2009-01-08 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.3.0]octane compounds
EA201070091A1 (ru) 2007-07-03 2010-06-30 Глэксо Груп Лимитед Производные пиперидина, пригодные в качестве антагонистов рецептора орексина
CN101687321B (zh) 2007-07-05 2012-08-08 松下电器产业株式会社 机器人手臂的控制装置及控制方法、机器人及控制程序
AR067665A1 (es) 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
ATE493386T1 (de) 2007-07-27 2011-01-15 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
NZ583487A (en) 2007-07-27 2011-09-30 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
EP2207778A2 (en) 2007-09-24 2010-07-21 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
KR101213007B1 (ko) 2007-12-18 2012-12-20 액테리온 파마슈티칼 리미티드 Ａｌｘ 작용제로서의 아미노트리아졸 유도체
NZ588080A (en) 2008-02-21 2012-04-27 Actelion Pharmaceuticals Ltd 2-Aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
CA2729985A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
AU2009305005A1 (en) 2008-10-14 2010-04-22 Actelion Pharmaceuticals Ltd Phenethylamide derivatives and their heterocyclic analogues
JP2012506375A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
EP2358711A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2010060471A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
JP2012509912A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
UY32277A (es) 2008-12-02 2010-05-31 Glaxo Group Ltd Derivados de n-{[1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0-il}metil}-2heteroarilamina y uso de los mismos
BRPI0922353A2 (pt) 2008-12-02 2018-06-05 Glaxo Group Ltd Derivados de n-{[(1r,4s, 6r-3- (2-piridinilcarbonil) - 3azabiciclo [4.1.0] hept-4-il] metil}-2-heteroarilamina e usos dos mesmos
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
US20120035214A1 (en) 2009-04-03 2012-02-09 Merck Canada Inc. Renin inhibitors
EP2421850A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited 3 -azabicyclo [4.1.0]heptanes used as orexin antagonists
NZ597453A (en) 2009-06-09 2013-03-28 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives as alxr agonists
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
DK3093291T3 (da) 2009-10-23 2019-07-29 Janssen Pharmaceutica Nv Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer
CA2788363A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2619195A1 (en) 2010-09-24 2013-07-31 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
LT2855453T (lt) 2012-06-04 2017-02-27 Actelion Pharmaceuticals Ltd. Benzimidazolo prolino dariniai
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists

Also Published As

Publication number Publication date
KR20150064753A (ko) 2015-06-11
EA201500399A1 (ru) 2015-09-30
CN104703980B (zh) 2017-09-22
CN104703980A (zh) 2015-06-10
EP2906553B1 (en) 2019-06-26
JP2015533157A (ja) 2015-11-19
PH12015500627A1 (en) 2015-05-11
TW201414727A (zh) 2014-04-16
AU2013328301A1 (en) 2015-05-28
US9493446B2 (en) 2016-11-15
WO2014057435A1 (en) 2014-04-17
AR092955A1 (es) 2015-05-06
SG11201502493XA (en) 2015-04-29
IL238052A0 (en) 2015-05-31
EP2906553A1 (en) 2015-08-19
JP6244365B2 (ja) 2017-12-06
KR102151288B1 (ko) 2020-09-03
CA2885180A1 (en) 2014-04-17
US20150252032A1 (en) 2015-09-10
AU2013328301A8 (en) 2015-06-11
MX2015004638A (es) 2015-07-14
BR112015007516A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
CA2885180C (en) Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
US11040966B2 (en) Benzimidazole-proline derivatives
IL285246B2 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
US9403813B2 (en) Azetidine amide derivatives as orexin receptor antagonists
WO2013050938A1 (en) 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
WO2016201168A1 (en) Oxadiazine compounds and methods of use thereof
CA2991404A1 (en) Imide derivatives and use thereof as medicine
EA047337B1 (ru) Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора
HK1208449B (en) Benzimidazole-proline derivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180919